ABC Labs unified under newly formed EAG Laboratories

By Melissa Fassbender contact

- Last updated on GMT

ABC Laboratories was initially acquired in July 2015. (Image: iStock/Gajus)
ABC Laboratories was initially acquired in July 2015. (Image: iStock/Gajus)

Related tags: Contract research organization, Laboratory

The independent lab network has combined 11 of its brands, including ABC Laboratories, to reside under a single company in order to “leverage cross functional capabilities,” says CEO.

Moving forward, the contract research organization (CRO) ABC Labs will be known as EAG Laboratories, a new entity that will provide a range of testing, analytical, and characterization services.

Siddhartha Kadia, EAG Laboratories president & CEO, told us that the life science market is a “key growth engine​” for the company and the pharma market represents a significant part of that growth.

EAG Laboratories already has a line of small molecule programs and is expanding its capabilities to support the biopharmaceutical market.

As part of that, we see a great opportunity with extractables and leachables testing for drug development, packaging, various delivery mechanisms as well as increasingly in biological manufacturing processes with single use systems​,” added Kadia.

The company is also able to do trace metal analysis and can complete all of its testing under both GMP and GLP requirements.

Kadia explained that the company will continue to invest, both organically and additively, in areas that complement or augment EAG’s current offerings.

An intersection of disciplines

ABC Labs was acquired by EAG Inc. in July 2015, making it the company's most recent acquisition.

Integration was expected to be “slow, deliberate and well-planned,​” ABC told us at the time​ – and it seems to have gone as predicted, with integration completed almost exactly a year after the initial announcement.

As reported, EAG was interested in ABC Labs in part for its analytical testing services, including development and cGMP and GLP-compliant testing capabilities for small and large molecule therapies and medical devices. The acquisition strengthened the company’s existing services in the US and Europe.

We believe that most important discoveries happen at the intersection of disciplines​,” said Kadia, as the company has made significant acquisition over the past couple years.

For the last two years we have been integrating these laboratories with our business processes​,” he added. “Bringing these capabilities together now under one brand, one company, allows us to share best practices and leverage cross functional capabilities to solve complex problems​.”

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more